Published online February 11, 2008
doi:10.1084/jem.20080167
The Journal of Experimental Medicine, Vol. 205, No. 2, 271-274
The Rockefeller University Press, 0022-1007 $30.00
© 2008 DeLeo et al.
An antidote for Staphylococcus aureus pneumonia?
Frank R. DeLeo and
Michael Otto
F.R. DeLeo and M. Otto are at the Laboratory of Human Bacterial Pathogenesis, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840
CORRESPONDENCE F.R.D.: fdeleo{at}niaid.nih.gov
ABSTRACT
Methicillin-resistant Staphylococcus aureus (MRSA) is the leading cause of bacterial infections in the United States. Severe invasive MRSA infections, which include pneumonia, are difficult to treat because the bacteria are resistant to antibiotics. A new report now shows that immunization against
-hemolysin (Hla), a cytolytic toxin secreted by most S. aureus strains, protects mice against lethal pneumonia. This finding represents the first successful vaccine strategy for the treatment of staphylococcal pneumonia.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Related Article
-
Vaccine protection against Staphylococcus aureus pneumonia
- Juliane Bubeck Wardenburg and Olaf Schneewind
J. Exp. Med. 2008 205: 287-294.
[Abstract]
[Full Text]
[PDF]